TLR7 enables cross-presentation by multiple dendritic cell subsets through a type I IFN-dependent pathway.

Area of Science:

• Immunology
• Vaccinology
• Molecular Medicine

Background:

• Conjugating Toll-like receptor (TLR) agonists to antigens enhances cellular immunity, but the underlying molecular mechanisms remain unclear.
• Understanding these mediators is crucial for developing effective vaccine strategies.

Purpose of the Study:

• To identify the molecular and cellular mediators of cross-priming induced by TLR7 agonist-antigen conjugates.
• To elucidate the roles of Type I IFN and IL-12 in TLR7-driven immune responses.

Main Methods:

• Utilized TLR7 agonist-antigen conjugates in immunological assays.
• Investigated the requirement of Type I IFN and IL-12 signaling pathways.
• Analyzed dendritic cell (DC) recruitment, activation, and antigen presentation capabilities.
• Evaluated CD8+ T-cell priming and expansion in vitro and in vivo.

Main Results:

• Type I IFN and IL-12 are critical mediators of TLR7-driven cross-priming.
• Type I IFN signaling is essential for DC recruitment and accumulation in lymph nodes.
• IL-12 is indispensable for cross-priming but does not directly regulate DC function.
• Langerhans cells, alongside dermal and CD8α(+) DCs, potently cross-present antigens and support CD8+ T-cell expansion.

Conclusions:

• TLR7 agonist-antigen conjugates elicit CD8+ T-cell responses via a Type I IFN and IL-12 codependent mechanism.
• The coordinated action of tissue-derived and lymphoid-resident DCs, influenced by these cytokines, drives effective T-cell immunity.